Tier 2 — strong
Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson's disease
iScience
2023
26; 3; 106278
Bibliography
- PubMed
- PMID 36936793
- PubMed Central
- PMC10014306
- Funding
- Research Council of Norway, Bergen Research Foundation and Western Norway Regional Health Authority support.
- Competing interests
- Two authors disclosed a patent application concerning NR for Parkinson’s disease.
Study snapshot
| Design | Secondary or companion analysis of an existing human intervention |
|---|---|
| Model | Human participants |
| Sample | 29 people with Parkinson’s disease |
| Intervention | NR versus placebo in the NADPARK trial |
| Duration | Up to 30 days |
| Endpoints | DNA methylation; one-carbon metabolism measures |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- NR with Resveratrol, Pterostilbene or TMG: Combination EvidenceNR with resveratrol, pterostilbene, TMG and quercetin: randomized findings, methylation evidence, combination safety and the limits of synergy claims.Read analysis
- NR and Parkinson’s Disease: NADPARK, NR-SAFE and NOPARKNR and Parkinson’s disease: NOPARK 2026 results, NADPARK, NR-SAFE, clinical scales, dose limits and what the evidence means for care.Read analysis
- NR Side Effects and Safety: Interactions and Who Should Avoid ItNR side effects and safety: placebo-controlled findings, flushing, digestion, sleep, medicines, methylation, pregnancy and long-term evidence limits.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
